

Kyowa Hakko Kirin Co., Ltd.

Ohtemachi Building, 1-6-1 Ohtemachi, Chiyoda-ku, Tokyo 100-8185, Japan
TEL: +81-3-3282-0007 FAX: +81-3-3284-1968 <http://www.kyowa-kirin.co.jp>



KYOWA KIRIN

Corporate Profile

Kyowa Hakko Kirin will be a “Japan-based world-leading R&D type life science company” contributing to the health and comfort of people around the world through biotechnologies.

In the core fields of cancer, renal diseases and immune system disorders, Kyowa Hakko Kirin leverages leading-edge biotechnologies centered on antibody technologies, to continually discover innovative new drugs and to develop and market those drugs world-widely. In this way, we are working to realize our vision of becoming a Japan-based global specialty pharmaceutical company that contributes to the health and comfort of people around the world.

The mission of Kyowa Hakko Kirin is to respond earnestly to the needs of patients who are suffering from diseases for which no effective treatments are available, their families, and the health care professionals fighting the diseases at the frontline and to pile up such efforts one by one. To fulfill this mission, we are continuously working to enhance our R&D capabilities, centered on therapeutic antibodies. We have given careful consideration to our own values, and as a result we have established “Commitment to Life”, which outlines the spirit and aspirations that unite the people who work at Kyowa Hakko Kirin. Even as we continue to take on new challenges and make new progress in the years ahead, we will return to these values each day.

The Kyowa Hakko Kirin Group is pursuing global growth by whole-group coordination and cooperation. Its core companies include “Kyowa Hakko Kirin” aiming at creation of new revolutionary drugs, “Kyowa Medex” promoting personalized medicine in diagnostic reagents business, and “Kyowa Hakko Bio” engaged in a wide range of business activities including amino acids, drug substances and intermediates, and supplements utilizing industry-leading fermentation and synthesis technologies.

The Group will never neglect its responsibility to maintain the highest standards of quality assurance, environmental and safety management, and compliance to ethical business practices, and we will continue to do our utmost to conduct our business with a high level of transparency. As we work to achieve our goals, I would like to ask for your continued support now and in the future.

Nobuo Hanai

President & Chief Executive Officer
Kyowa Hakko Kirin Co., Ltd.



The pathway to “Commitment to Life”

Towards our aspirations, as pharmaceutical company employees, to face up to life with sincerity and continue to move ahead, along with medical practitioners, to bring smiles to all people who are fighting against diseases

Let Us Create the Philosophy of a New Company with Our Own Hands!

Kyowa Hakko Kirin is a pharmaceutical company formed through the integration of Kyowa Hakko's Pharmaceuticals business division and Kirin Pharma.

Each and every one of our employees works at the new company with the same aspirations, sharing their values. To accomplish this, more than 1,000 employees reflected on themselves anew and expressed glowing feelings for each other by transcending the boundaries of age and job title in order to create the philosophy of a new company with our own hands.

Examine “what we should value”

- “The meaning of the company’s existence:” Why does Kyowa Hakko Kirin exist?
- “Value of supplying pharmaceuticals:” What can Kyowa Hakko Kirin’s pharmaceuticals do?
- “Employee code of conduct:” What kind of code of ethics should we, Kyowa Hakko Kirin’s employees, follow?



Things we must not forget and should continue to place value on:



Innumerable Aspirations Condensed into “Commitment to Life”

Each and every one of our employees condensed his/her diverse aspirations from various viewpoints into “Commitment to Life”.

It reflects our aspirations, as employees of a pharmaceutical company, for facing up to life with sincerity and continuing to move ahead with life, along with medical practitioners, in order to bring smiles to all people who are fighting against diseases.



With Drugs, We Want to Bring Smiles to People Fighting against Diseases

As employees of a pharmaceutical company, we are aiming at bringing the flowers of smiles to all people facing up to life with the mission of working for precious life every day, always bearing “Commitment to Life” in our mind.

Commitment to Life

Countless precious lives surround us.

Brought into this world, blessed, raised with loving care—full of dreams, happiness as the goal of life.

Deeply instill in us, and know that what we work for—the most precious presence of all on this planet.

Infinite possibilities for us, a pharmaceutical company.

Believe in ourselves, believe in our power, believe in what we have built together.

Not a large company, but with qualities like none other

History so unique we can be proud of, technology unmatched,

And superior human beings that cannot be found elsewhere.

Be brave; do not shy away from challenges. Have passion; break away from the norm.

Innovation is not just about growth—but instead a leap towards the future, a grand growth with wings.

Wings never to be given to those who settle for the status-quo.

Don't just make medicine. Make people smile, bring light to their lives.

How strongly one longs to live. How deeply one is loved by their loved ones.

How sincerely one desires to help the one life they dedicate themselves to in the field of medicine.

Stay receptive, sharpen your sensitivities.

Let us become the top company in the world who cares the most for life.

Strength is not what saves the world. A caring heart is what the world calls for.

Strive to become a superb team.

One human being, excellent or not, is ever so powerless, as a power of one, mistakes, even a possibility.

Show the world the excellence of coming together. Amazing results, when we become one.

Be driven. Think of those fighting for their lives every day.

Their strong devotion to life speaks to our hearts.

Hurry—do not scurry, but we must not stand still. Stay sincere, always—may that be our vow.

We make medicine. This is, our walk of life.

Work, can bring happiness. Remember this, always.

Born on this planet in various parts of the globe, passing through life in different ways,

And like a miracle we found one another—our jobs, our team, our company.

Know this, and be fulfilled, always.

Be thankful of what you have, pour your heart and soul into the mission you were given,

Be proud of your work, the work to save precious lives.

We are, each and everyone of us, Kyowa Hakko Kirin.

Taking the walk of life, one life at a time.

Diseases know no borders, and neither does Kyowa Hakko Kirin.



We bring innovative pharmaceuticals into the world.

Our aim is to ensure that the maximum number of people can access our products in a timely manner.

Thus, we are making full use of our unique drug development technologies and biomedical engineering and we are globalizing our research and development systems.

From Research to Marketing of Pharmaceuticals

In every step of the 6 stages of the process from research and development to manufacturing and marketing of pharmaceuticals, we exploit all our technology and know-how.



technologies to expand our business,

5

Production / Quality Assurance

In order to ensure the shipping of products that meet global quality standards, our five plants in Japan boast the latest in manufacturing technology and equipment and employ a quality assurance system that rigorously checks every step from the drug substance to the drug products.

6

MR Activities

Our 1,400 medical representatives in 65 sales offices around Japan provide high-quality information that benefits both patients and everyone involved in medical care. In addition, overseas marketing networks in Asia, Europe and America are also steadily expanding.

[Overseas bases]

- A BioWa, Inc. / Princeton, U.S.A.*¹
- B Kyowa Hakko Kirin Pharma, Inc. / Princeton, U.S.A. 4
- C Kyowa Hakko Kirin America, Inc. / Princeton, U.S.A.*²
- D Hematech, Inc. / South Dakota, U.S.A. 1
- E Kyowa Hakko Kirin California, Inc. / California, U.S.A. 1 2 4
- F ProStrakan Group plc / Scotland, United Kingdom 4 6
- G Kirin Kunpeng (China) Bio-Pharmaceutical Co., Ltd. / Shanghai 4 5 6
- H Jeil-Kirin Pharmaceutical Inc. / Seoul, Korea 4 6
- I Kyowa Hakko Kirin (Taiwan) Co., Ltd. / Taipei 4 6
- J Kyowa Hakko Kirin (Hong Kong) Co., Ltd. / Hong Kong 6
- K Kyowa Hakko Kirin (Singapore) Pte. Ltd. / Singapore 6
- L Kyowa Hakko Kirin (Thailand) Co., Ltd. / Thailand 6

*1 Licensing business activities

*2 The U.S. holding company

Kyowa Hakko Kirin Co., Ltd. / Japan

Putting Our Overseas Networks to Work


The initial aim of our overseas business strategy is to maximize the value of the core antibody business of Kyowa Hakko Kirin.

Specifically, we will continue to move forward with the global standardization of our enhanced antibody activity technologies, including the POTELLIGENT® technology, and broaden the alliance network worldwide to acquire new antigens and antibodies.

We are also working for the early acquisition of primary patent rights. In addition, we will establish a long-term profit base in the key business area of Asia by enhancing our product lineup and undertaking the strategic integration of business operations in China. We are also formulating strategies to develop sales channels in Europe and America that will ensure our global network.

We expand the frontiers of pharmaceutical development with antibody technology backed by cutting-edge biotechnology.

The human body has an amazing natural mechanism of protection against disease called the immune system. It creates antibodies to fight foreign substances in the body such as disease-causing bacteria. Among the many strengths of Kyowa Hakko Kirin, our therapeutic antibodies that tap the power of the immune system and originally developed antibody engineering technologies hold a unique key to the effective treatment of many diseases. The creation of these and other unique technologies contribute to improved medical care and protection of the health and future of humankind.



World's largest class equipments for manufacturing therapeutic antibodies

Japan's leading facility for manufacturing therapeutic antibodies is in operation

In March 2010, the facility for manufacturing therapeutic antibodies started operation at the Bio Process Research and Development Laboratories in Takasaki, Gunma Prefecture. The facility has equipments graded as the world's largest class for the culture and purification for recombinant mammalian cells. Designed for acceleration of the development of the therapeutic antibody pipeline, it can handle the manufacture of antibodies for a variety of scale.



The facility for manufacturing therapeutic antibodies

Enhanced Antibodies Activity Technology


Two technologies expected to lead to promising pharmaceuticals

Kyowa Hakko Kirin's originally developed ADCC enhanced antibody activity technology (POTELLIGENT® Technology) and CDC enhanced antibody activity technology (COMPLEGENT® Technology) are not only applied to the development of in-house therapeutic antibodies, but also serve as core technologies that form a platform for aggressive and strategic alliances in the development and marketing of therapeutic antibodies and accelerate our expansion in this business field.

ADCC enhanced antibody activity technology enables more effective elimination of target cells

POTELLIGENT®


The ADCC (Antibody-dependent cellular cytotoxicity) mechanism is one of the immunological functions of humans allowing white blood cells like natural killer cells and monocytes to exterminate target cells in the presence of antibodies. The main feature of Kyowa Hakko Kirin's independently developed ADCC enhanced antibody activity technology POTELLIGENT® is its ability to remarkably increase the ADCC activity by removing the fucose in the carbohydrate structure of antibodies, thus causing the extremely effective elimination of target cells, such as cancer cells. Experiments using animals have shown dramatically higher anti-tumor effects in antibodies using POTELLIGENT® technology in comparison with conventional antibodies. Accordingly, these antibodies made with POTELLIGENT® are being developed as anti-cancer agents. Furthermore, development is underway for the use of these antibodies in the treatment of immune and allergy disorders.



CDC enhanced antibody activity technology multiplies the efficacy of antibody drugs

COMPLEGENT®


CDC (Complement dependent cytotoxicity) is a mechanism which acts to destroy target cells through complements. The CDC activity is, like that of ADCC, one of the primary means of bringing out the effective potential of therapeutic antibodies. Kyowa Hakko Kirin developed the CDC enhanced antibody activity technology COMPLEGENT® to enhance the activity of therapeutic antibodies, just as POTELLIGENT® is designed to do. The combined use of COMPLEGENT® and POTELLIGENT® technologies will allow us to produce ground-breaking therapeutic antibodies with both powerfully enhanced ADCC and CDC mechanisms.



Fully Human Antibody Production Technology

Epoch-making Human Artificial Chromosome (HAC) technology

The conventional gene transfer method allows just for partial transfer of human antibody genes into a mouse due to their large size. However, Kyowa Hakko Kirin pioneered an epochal technique (HAC: Human Artificial Chromosome) of transferring a fragment of a human chromosome containing a very large cluster of genes into a mouse.



World's leading human antibody-producing mouse (KM Mouse)

Created by combining Kyowa Hakko Kirin's HAC technology and the U.S. company Medarex's (currently Bristol-Myers Squibb's) human antibody producing technology, the Human Antibody Producing Mouse (KM Mouse) is recognized around the world as the most advanced technology of its kind. This achievement has resulted in the creation of antibody-producing mice that can generate fully human antibodies with the same diversity as naturally produced human antibodies, and has expanded the potential of therapeutic application.


Human antibody-producing bovine holds even more possibilities for antibody pharmaceuticals

Hematech, Inc., U.S. subsidiary of Kyowa Hakko Kirin, successfully generated human-antibody producing bovine through combination of Kyowa Hakko Kirin's HAC technology and gene targeting technology with Hematech's bovine cloning technology. These bovine produce fully human antibodies, and by immunizing them with antigens, it is expected to generate a variety of antibodies, which could be a source of unique therapeutic antibodies.



Focusing on oncology, nephrology and immunology/allergy, we endeavor to accelerate R&D in the treatment of these diseases.

Kyowa Hakko Kirin is striving to create innovative value in pharmaceuticals by positioning oncology, nephrology and immunology/allergy as the core fields of its research and development. We believe that this specialized focus on these three sectors will lead to significant acceleration of our capability to develop effective pharmaceutical solutions. Kyowa Hakko Kirin is striving to develop innovative new therapeutic antibodies by combining technologies such as POTELLIGENT® and the Human Antibody Producing Mouse. In small molecule pharmaceuticals, we are working to speed up development and enhance our pipeline through the fusion of our acquired technologies.



Main Products

Here are some of the main products of Kyowa Hakko Kirin—all produced using cutting-edge manufacturing technology and equipment and under our strict quality assurance system and in full compliance with global standards.

ESPO® / NESP®

ESPO® is a glycoprotein, human erythropoietin, produced by using the technology of genetic recombination. Its specific pharmacological effect of increasing erythrocytes allows it to act as an anemia-relieving treatment for dialysis patients. It is also used for the treatment of anemia found in premature infants, renal anemia during CAPD (continuous ambulatory peritoneal dialysis) and before dialysis initiation, as well as for autologous blood transfusion.

NESP® is a new anti-anemia agent that attaches new sugar chains through partial modification of the amino acid sequence of human erythropoietin (EPO). In comparison to previous erythropoietin preparations, it exhibits a sustained increase of erythrocytes. As such, it has the vital characteristic of correcting anemia with smaller doses than had been required previously.



GRAN®

GRAN® is a protein produced by genetic recombination technology. It works to selectively increase the count of a type of white cell called neutrophil, as well as increase their functional efficacy. This enables a quick recovery from neutropenia occurring as a result of cancer chemotherapy and reduces the risk of infection, allowing for more effective chemotherapy. It is also used for PBSCT (peripheral blood stem cell transfusion) mobilization, and the relief of congenital neutropenia or neutropenia occurring after hematopoietic stem-cell transplantation (such as bone-marrow transplants).



Romiplate®

Romiplate®, a genetically recombinant protein, stimulates platelet production via stimulation of the thrombopoietin receptors. It is for chronic Idiopathic Thrombocytopenic Purpura (ITP) patients, and serves to improve platelet counts by stimulating platelet production.



CONIEL®

CONIEL® is the nation's first long-acting calcium antagonist (generic name benidipine hydrochloride) in Japan and effective against both hypertension and angina pectoris. It has been demonstrated that this drug has a high affinity for the vascular smooth muscle cell membrane and that its antihypertensive and other pharmacological effects are sustained over a long period.



REGPARA®

REGPARA® is a new class of agent for treatment of secondary hyperparathyroidism. REGPARA® acts on parathyroid calcium receptor directly and suppresses parathyroid hormone secretion, while simultaneously lowering serum calcium and phosphorus levels.



ALLELOCK® / Patanol®

ALLELOCK® (generic name olopatadine hydrochloride) is a medicine for patients with various types of allergies. It exhibits potent and selective antihistamine activity, and suppresses various symptoms of allergies. It relieves the three major symptoms of pollinosis or allergic rhinitis (sneezing, rhinorrhea and nasal congestion), as well as itching associated with chronic urticaria and skin diseases.

The active ingredient of the antiallergic eye drops Patanol® is the same olopatadine hydrochloride. The product was developed, manufactured, and marketed by the Alcon Group. It is approved for sale in 105 countries worldwide.



DEPAKENE® / TOPINA®

DEPAKENE® is an antiepileptic agent with sodium valproate as its active ingredient that proved to be highly effective administered alone. It comes in various dosage forms to meet different clinical needs. In addition to treating various types of epilepsy and behavioral or personality disorders resulting from epilepsy, it is also used to treat mania and manic depression.

TOPINA® is an antiepileptic agent whose active ingredient is topiramate. Administered in combination with other medicines, it is effective against epilepsy with partial seizures (including secondary generalized seizures), against which other treatments have not yet been shown to be fully effective. It is highly effective in enhancing the quality of life of intractable epilepsy patients.



Advancing toward a prosperous future together with society—Kyowa Hakko Kirin is committed to fulfilling its corporate social responsibility (CSR) on the basis of the ISO 26000 Guidance on social responsibility.

Commitment to organizational governance

Kyowa Hakko Kirin is consistently strengthening ethical governance and risk management to become an even more trusted company. We conduct our business under a management system and organization developed to meet this goal, and are working hard to maintain the highest standards of corporate governance to ensure increased transparency and effective management oversight. A Group Risk Management System is also in place to allow us to prevent serious risks from materializing and causing damage to customers and our business, and to take appropriate measures swiftly if any incident should occur.

Commitment to promoting human rights and proper labor practices

Kyowa Hakko Kirin values employees' self-initiative, encourages them to improve their abilities and creativeness, and endeavors to create a work environment in which they can pursue their own infinite possibilities and be fully motivated at work. Under the Diversity & Inclusion Project, a cross-company project launched in October 2010, we are promoting activities aimed at creating a corporate culture in which gender, nationality, stage of life, disability, or how employees joined the company will not present any barrier for those seeking to further their careers.




Commitment to protecting the environment

Through the entire life cycle of our products from their development to disposal, we give careful consideration to each product's environmental impact and safety. In this spirit of responsible care, we have voluntarily set our high standards for environment and occupational health and safety using international standards as a guideline. Our organizational structure and group-wide management systems are built to achieve these standards and to elevate the level of our environmental and safety performance even further. We are also committed to achieving and maintaining a low carbon footprint across the supply chain by fully implementing our ISO 14001 environmental management system.

Commitment to promoting fair operating practices and addressing consumer issues

In order to ensure that we become even more credible and widely accepted in society, we have formulated the Kyowa Hakko Kirin Group Compliance Guidelines; our employees have become familiar with these guidelines through regularly conducted training and education programs. A handbook summarizing compliance requirements in the Pharmaceutical business in Japan has also been created and distributed to all employees in Japan as a guideline for helping them make legally and ethically appropriate decisions. Furthermore, to consistently deliver products that will earn the trust and satisfaction of customers, each manufacturing plant is working to build, maintain and improve quality assurance systems that meet the ICH Q10 specifications, while also complying with the latest laws and regulations, such as the revised Pharmaceutical Affairs Act, to maintain reliable production and quality control. The quality of pharmaceuticals is not, however, solely determined by the product itself but also encompasses the provision of information on side effects and other matters to ensure safe use of the product. Our medical representatives (MRs) act as pharmaceutical information specialists, and visit medical institutions regularly to provide and gather information necessary for the proper use of pharmaceuticals.



Commitment to community involvement and development

As a good corporate citizen, we are involved in a wide variety of activities aimed at maintaining a favorable relationship with all stakeholders and realizing a prosperous future together with society. These activities include enhancing the safety of communities in which our plants are located, participating in dialogs with residents, providing a stable supply of pharmaceuticals to developing countries, and promoting the field of bioscience.



Company Name	Kyowa Hakko Kirin Co., Ltd.
Established	July 1, 1949 * Company name changed from Kyowa Hakko Kogyo Co., Ltd. following merger with Kirin Pharma Company, Limited on October 1, 2008.
Capital	¥26,745million (As of December 31, 2011)
Number of Employees	7,229 (Consolidated base, As of December 31, 2011)
President & CEO	Nobuo Hanai
Head Office	Ohtemachi Building, 1-6-1 Ohtemachi,Chiyoda-ku, Tokyo 100-8185, Japan TEL: +81-3-3282-0007 FAX: +81-3-3284-1968
Consolidated Sales	¥343,722million (the year ended in December 31, 2011)
Main Business	Kyowa Hakko Kirin Co., Ltd. is engaged in the manufacturing and marketing of medical products and pharmaceuticals. As the holding company of the Kyowa Hakko Kirin Group, it manages the business activities in the Bio-Chemicals segment.
Parent Company	Kirin Holdings Company, Limited

Our Products

Here are some of the main products of Kyowa Hakko Kirin—all produced using cutting-edge manufacturing technology and equipment and under our strict quality assurance system and in full compliance with global standards.

Therapeutic area	Product name
ESA (Erythropoietic Stimulating Agent) preparation	ESPO®, NESP®
TPO-receptor agonist	Romiplate®
Agent for hypertension and angina pectoris	CONIEL®
Agent for hypertension	COVERSYL®
Anticancer agent	MITOMYCIN C, 5-FU, ADRIACIN®, Navelbine®
G-CSF (Granulocyte Colony Stimulating Factor) preparation	GRAN®
Antiepilepsy agent	DEPAKENE®, TOPINA®
Agent for secondary hyperparathyroidism	REGPARA®, Rocaltrol®
Acute circulatory failure agent	INOVAN®, PRe DOPA
Antiallergic	ALLELOCK®, CELTECT®, Patanol®
Gastrointestinal agent	NAUZELIN®
Agent for ulcerative colitis	ASACOL®
Agent for hyperphosphatemia	PHOSBLOCK®
Agent used in advance of hematopoietic stem cell transplants	Busulfex®
Agent for nocturnal incontinence	DESMOPRESSIN-Spray

Kyowa Hakko Kirin Group

The Group Management Philosophy

The Kyowa Hakko Kirin Group companies strive to contribute to the health and well-being of people around the world by creating new value through the pursuit of advances in life sciences and technologies.

The Group Vision

To create a Japan-based, leading world-class Japanese research and development-centered life sciences company focusing on pharmaceuticals with a firm foundation in biotechnology.

Group Organization Chart

Kyowa Hakko Kirin Co., Ltd.

100% subsidiary

100% subsidiary

KYOWA HAKKO BIO CO., LTD.

[Major products] Pharmaceutical products, Health care products

[Bio-Chemicals business]

Utilizing fermentative production technologies, Kyowa Hakko Bio is manufacturing useful substances, including amino acids, nucleic acids and related compounds, substances, vitamins and physiological active substances. The company is contributing to the health and well-being of people around the world by supplying raw materials for pharmaceuticals, health food and its raw materials, and cosmetics in response to globally increasing demand for high-value added amino acids for use in pharmaceuticals and needs of the market for specialty generic drugs.

100% subsidiary

Kyowa Medex Co., Ltd.

[Major products] In vitro diagnostics, Medical instruments

[Pharmaceuticals business]

Kyowa Medex plays an important part in Kyowa Hakko Kirin's Pharmaceuticals business, as well as in bringing health and well-being to people around the world, through the development, production, and sales of in vitro diagnostics and medical instruments. The company's products include reagents for use in the measurement of cholesterol and neutral fat for the diagnosis of hyper-lipidemia; reagents for HbA1c measurement to examine blood glucose control levels; and medical instruments that meet the needs of point-of-care testing.

Main Business Offices

Our headquarters in the heart of Tokyo oversees and coordinates the operations of the 65 domestic sales offices as well as of the five state-of-the-art research laboratories that drive our pharmaceutical business and the plants that are fully compliant with international standards of quality control. Providing total support in every stage from development to marketing, Kyowa Hakko Kirin Co., Ltd. is ready to meet any challenge.

Branch Offices		
Sapporo Branch Davinci Sapporo Park Front 5F, 7-1-1 Odorinishi, Chuo-ku, Sapporo-shi, Hokkaido 060-0042 TEL: +81-11-261-3127 FAX: +81-11-261-2584	Nagoya Branch CRD Marunouchi 10F, 3-17-13 Marunouchi, Naka-ku, Nagoya-shi, Aichi 460-0002 TEL: +81-52-962-1091 FAX: +81-52-962-5243	Shikoku Branch Matsuyama Daiichi Seimei Building 9F, 3-2-11 Ichiban-cho, Matsuyama-shi, Ehime 790-0001 TEL: +81-89-945-1288 FAX: +81-89-932-1237
Tohoku Branch Sendai Hashimoto Building 9F, 27-21 Tachi-machi, Aoba-ku, Sendai-shi, Miyagi 980-0822 TEL: +81-22-262-7691 FAX: +81-22-223-6563	Osaka Branch, Keiji-Hokuriku Branch Dojima Avanza 14F, 1-6-20 Dojima, Kita-ku, Osaka-shi, Osaka 530-8280 TEL: +81-6-6346-6900 FAX: +81-6-6346-6825	Kyushu Branch Fukuoka Center Building 13F, 2-2-1 Hakataekimae, Hakata-ku, Fukuoka-shi, Fukuoka 812-8663 TEL: +81-92-473-5631 FAX: +81-92-475-4573
Tokyo Branch, Chiba-Saitama Branch, Kita-Kanto Branch, Koshinetsu Branch, Yokohama Branch Riverside Yomiuri Building 13F, 36-2 Nihonbashi-Hakozaki-cho, Chuo-ku, Tokyo 103-8503 TEL: +81-3-5641-8600 FAX: +81-3-5641-8681	Chugoku Branch Hiroshima Inarimachi Daiichi Seimei Building 7F, 2-16 Inari-machi, Minami-ku, Hiroshima-shi, Hiroshima 732-0827 TEL: +81-82-262-6680 FAX: +81-82-262-5242	
Research Laboratories		
Tokyo Research Park 3-6-6 Asahi-machi, Machida-shi, Tokyo 194-8533 TEL: +81-42-725-2555 FAX: +81-42-726-8330	Bio Process Research and Development Laboratories 100-1 Hagiwara-machi, Takasaki-shi, Gunma 370-0013 TEL: +81-27-353-2011 FAX: +81-27-353-2123	Chemical Process Research and Development Laboratories 1-1-53 Takasu-cho, Sakai-ku, Sakai-shi, Osaka 590-8554 TEL: +81-72-223-5554 FAX: +81-72-227-7214
Fuji Research Park 1188 Shimotogari, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8731 TEL: +81-55-989-2004 FAX: +81-55-986-7430	Drug Formulation Research and Development Laboratories 1188 Shimotogari, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8731 TEL: +81-55-989-2004 FAX: +81-55-986-7430	

Plants		
Takasaki Plant 100-1 Hagiwara-machi, Taksaki-shi, Gunma 370-0013 TEL: +81-27-353-2011 FAX: +81-27-353-2123	Yokkaichi Plant 2-3 Daikyo-cho, Yokkaichi-shi, Mie 510-8502 TEL: +81-59-331-5149 FAX: +81-59-331-5177	Ube Plant 2547-3 Fujimagari, Ube-shi, Yamaguchi 755-8501 TEL: +81-836-22-5508 FAX: +81-836-22-5534
Fuji Plant 1188 Shimotogari, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8731 TEL: +81-55-986-7600 FAX: +81-55-989-2091	Sakai Plant 1-1-53 Takasu-cho, Sakai-shi, Osaka 590-8554 TEL: +81-72-223-5554 FAX: +81-72-227-7214	

Main Group Companies

Our business is global in vision and scale. We are working in close collaboration with our group companies in the pharmaceutical and biochemical industries to bring exciting new products to markets around the world.

Japan		
Kyowa Medex Co., Ltd. Harumi Island TORITON Square X- 4F, 1-8-10 Harumi, Chuo-ku, Tokyo 104-6004 TEL: +81-3-6219-7600 FAX: +81-3-6219-7614	Kyowa Medical Promotion Co., Ltd. Riverside Yomiuri Building, 36-2 Nihonbashi-Hakozaki-cho, Chuo-ku, Tokyo 103-0015 TEL: +81-3-5641-8658 FAX: +81-3-5641-8697	Kyowa Hakko Bio. Co., Ltd. *Bio-Chemicals business Ohtemachi Building 5F, 1-6-1 Ohtemachi, Chiyoda-ku, Tokyo 100-8185 TEL: +81-3-3282-0974 FAX: +81-3-3284-1802
Overseas		
U.S.A.	BioWa, Inc. / Princeton, U.S.A. 212 Carnegie Center, Suite 101, Princeton, NJ 08540, U.S.A. TEL: +1-609-580-7500 FAX: +1-609-580-7534	Hematech, Inc. / South Dakota, U.S.A. 4401 South Technology Drive, Sioux Falls, SD 57106, U.S.A. TEL: +1-605-361-6793 FAX: +1-605-361-9702
	Kyowa Hakko Kirin Pharma, Inc. / Princeton, U.S.A. 212 Carnegie Center, Suite 101, Princeton, NJ 08540, U.S.A. TEL: +1-609-919-1100 FAX: +1-609-919-1111	Kyowa Hakko Kirin California, Inc. / California, U.S.A. 9420 Athena Circle, La Jolla, CA 92037, U.S.A. TEL: +1-858-952-7000 FAX: +1-858-952-7001
	Kyowa Hakko Kirin America, Inc. / Princeton, U.S.A. 212 Carnegie Center, Suite 101, Princeton, NJ 08540, U.S.A. TEL: +1-609-580-7400 FAX: +1-609-919-1111	
Europe	ProStrakan Group plc / Scotland, United Kingdom Galabank Business Park, Galashiels TD1 1QH, United Kingdom TEL: +44-1896-664000 FAX: +44-1896-664001	
Asia	Kirin Kunpeng (China) Bio-Pharmaceutical Co., Ltd. / Shanghai 970 Long Dong Road, Z.J.High-Tech Park, Pudong New Area, Shanghai 201203, China TEL: +86-21-5080-0909 FAX: +86-21-5080-0026	Kyowa Hakko Kirin (Hong Kong) Co., Ltd. / Hong Kong Unit B, 13/F, Manulife Tower, 169 Electric Road, North Point, Hong Kong TEL: +852-2956-0828 FAX: +852-2956-1627
	Jeil-Kirin Pharmaceutical Inc. / Seoul, Korea 5F, Poonglim B/D, 823 Yeoksam-Dong, Kangnam-Ku, Seoul 135-080, Republic of Korea TEL: +82-2-3471-4321 FAX: +82-2-3471-4322	Kyowa Hakko Kirin (Singapore) Pte. Ltd. / Singapore 260, Orchard Road, #07-06 The Heeren, 238855, Singapore TEL: +65-6836-3991 FAX: +65-6836-3928
	Kyowa Hakko Kirin (Taiwan) Co., Ltd. / Taipei 9F, No.44, Sec 2, Chung Shan N. Road, Taipei 10448, Taiwan TEL: +886-2-2564-2800 FAX: +886-2-2560-1667	Kyowa Hakko Kirin (Thailand) Co., Ltd. / Thailand 20F, United Center Bldg., 323 Silom Road, Bangrak, Bangkok 10500, Thailand TEL: +66-2631-2126 FAX: +66-2631-2125